Vor Biopharma (NASDAQ:VOR) Stock Price Up 10% – What’s Next?

Vor Biopharma Inc. (NASDAQ:VOR) rose 10% during trading on Thursday . The company traded as high as $14.17 and last traded at $14.3010. Approximately 622,068 shares changed hands during mid-day trading, a decline of 35% from the average daily volume of 959,875 shares. The stock had previously closed at $13.00.

Analyst Upgrades and Downgrades

VOR has been the topic of a number of recent analyst reports. Wells Fargo & Company started coverage on Vor Biopharma in a research note on Thursday, March 19th. They issued an “overweight” rating and a $30.00 price objective on the stock. Wall Street Zen downgraded shares of Vor Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Jefferies Financial Group upgraded shares of Vor Biopharma to a “strong-buy” rating in a report on Thursday, April 30th. HC Wainwright reaffirmed a “buy” rating and issued a $31.00 price objective on shares of Vor Biopharma in a research note on Monday, May 18th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vor Biopharma in a research report on Monday, June 1st. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $42.25.

Vor Biopharma Price Performance

The business has a 50 day moving average price of $15.23 and a 200-day moving average price of $13.85.

Vor Biopharma (NASDAQ:VOR) last released its earnings results on Monday, March 30th. The company reported $307.61 EPS for the quarter. Sell-side analysts predict that Vor Biopharma Inc. will post -2.51 earnings per share for the current fiscal year.

Insider Buying and Selling at Vor Biopharma

In related news, Director Ra Capital Management, L.P. sold 165,150 shares of the business’s stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $15.77, for a total transaction of $2,604,415.50. Following the transaction, the director owned 2,402,095 shares in the company, valued at $37,881,038.15. The trade was a 6.43% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last three months, insiders have sold 3,002,903 shares of company stock valued at $49,412,176. Insiders own 0.27% of the company’s stock.

Hedge Funds Weigh In On Vor Biopharma

Several institutional investors have recently made changes to their positions in VOR. Goldman Sachs Group Inc. boosted its position in shares of Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after purchasing an additional 58,247 shares in the last quarter. Jane Street Group LLC acquired a new position in Vor Biopharma during the 1st quarter worth approximately $140,000. XTX Topco Ltd acquired a new position in Vor Biopharma during the 2nd quarter worth approximately $66,000. BNP Paribas Financial Markets boosted its holdings in Vor Biopharma by 497.3% in the third quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock worth $296,000 after acquiring an additional 5,058 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in Vor Biopharma in the third quarter valued at approximately $230,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).